Europese Unie - Sloveens - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - zdravila za obstruktivne pljučne bolezni, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Europese Unie - Sloveens - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - zdravila za obstruktivne pljučne bolezni, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Europese Unie - Sloveens - EMA (European Medicines Agency)

intervet international bv - orbifloxacin, mometasone furoate, posaconazole - otologi - psi - zdravljenje akutni otitis externa in akutne exacerbations ponavljajočih se otitis externa, povezane s bakterije občutljive za orbifloxacin in gliv dovzetni za posaconazole, zlasti malassezia pachydermatis.

Europese Unie - Sloveens - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - zdravila za obstruktivne pljučne bolezni, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Europese Unie - Sloveens - EMA (European Medicines Agency)

bayer animal health gmbh - florfenicol, terbinafine hidroklorid, mometasone furoate - otologicals, kortikosteroidi in antiinfectives v kombinaciji - psi - za zdravljenje akutnih udarci otitis externa ali akutno exacerbations ponavljajočih se otitis, ki jih povzročajo mešane okužbe dovzetni sevov bakterije občutljive za florfenicol (staphylococcus pseudintermedius) in gliv, občutljiv na terbinafine (malassezia pachydermatis).

Europese Unie - Sloveens - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - zdravila za obstruktivne pljučne bolezni, - alergijske asthmaxolair je navedeno pri odraslih, mladostnikih in otrocih (6 do.

Europese Unie - Sloveens - EMA (European Medicines Agency)

gilead sciences ireland uc - cobicistat - okužbe z virusom hiv - antivirusi za sistemsko uporabo - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.

Europese Unie - Sloveens - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, cobicistat, emtricitabine, tenofovir alafenamide - okužbe z virusom hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - zdravilo symtuza je indicirano za zdravljenje okužbe z virusom humane imunske pomanjkljivosti tipa 1 (hiv-1) pri odraslih in mladostnikih (starih 12 let in več, z telesno maso najmanj 40 kg). genotypic testing should guide the use of symtuza.

Europese Unie - Sloveens - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 in 5.

Europese Unie - Sloveens - EMA (European Medicines Agency)

janssen-cilag international n.v. - darunavir, cobicistat - okužbe z virusom hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - zdravilo rezolsta je indicirano v kombinaciji z drugimi protiretrovirusnimi zdravili za zdravljenje okužbe z virusom humane imunske pomanjkljivosti 1 (hiv 1) pri odraslih, starih 18 let ali več. genotipa testiranje mora vodnik za uporabo rezolsta.